Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (2,681,273)	$ (2,368,305)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	40,746	28,338
Accretion of debt discount	542,428	0
Stock Based Compensation	59,000	277,664
Changes in assets and liabilities:
Prepaid expenses and other receivables	94,059	263,022
Inventory	(125,311)	(170,371)
Accounts payable	(137,999)	59,010
Liability due to related party	(676,560)	100,533
Other liabilities and accrued expenses	(121,357)	(52,608)
Net cash used in operating activities	(3,006,267)	(1,862,717)
Cash Flows from Investing Activities:
Capitalized patent costs	(27,600)	(28,310)
Purchase of property and equipment	(14,032)	(133,716)
Net cash (used in) provided by investing activities	(41,632)	(162,026)
Cash Flows from Financing Activities:
Costs incurred in relation to equity financing	(957,193)	(9,575)
Commission paid on note payable	(325,000)	0
Proceeds from issuance of notes	5,000,000	0
Proceeds from issuance of common stock in relation to equity financing	15,750,672	152,492
Proceeds from warrant exercise	394,475	26,000
Repayments of note payable	(82,555)	0
Net cash provided by financing activities	19,780,399	168,917
Net (decrease) increase in cash	16,732,500	(1,855,826)
Effect of exchange rate changes on cash	110,332	(113,723)
Cash at beginning of period	106,107	3,740,664
Cash at end of period	16,948,939	1,771,115
Supplemental disclosure of non-cash financing activities:
Prepayment of equity compensation	$ 0	$ 85,715